PD-L1 IHC 22C3 pharmDx Nets Companion Diagnostic Approval for Pembrolizumab in Ovarian Cancer
#ovca #oncology
www.onclive.com/view/pd-l1-i...
0
0
0
0
#OVCA
Latest posts tagged with #OVCA on Bluesky
Trending
Posts tagged #OVCA
BREAKING 🚨: @fda.gov Approves Pembrolizumab Plus Paclitaxel +/- Bevacizumab for PD-L1+ PROC #ovca #gynsm #FDAapproved
Read more 📰: www.onclive.com/view/fda-app...
0
0
0
0
" ... technical & biological challenges that warrant further investigation. Larger prospective studies are necessary 2 refine ctDNA's #clinicalutility & integration into personalized #ovarian #cancer care." 2/2
Thx @lizswisher.bsky.social et al!!! #CanSky #ovca
pubmed.ncbi.nlm.nih.gov/41149505/
3
0
0
0
Vicky Makker, MD, Antonio Gonzalez-Martin, MD,
Dana Chase, MD, and Vanda Salutari, MD, highlight some of the top data in gynecologic oncology presented at #ESMO25
Watch and read their exclusive insights! #ovca #gynsm
www.onclive.com/view/emergin...
0
0
0
0
Stenoparib Monotherapy Yields Potential OS Benefit in Platinum-Resistant Ovarian Cancer #ovca #oncology www.onclive.com/view/stenopa...
0
0
0
0
Health Canada Approves Mirvetuximab Soravtansine for FRα+ Platinum-Resistant Epithelial Ovarian Cancer #ovca #oncology www.onclive.com/view/health-...
0
0
0
0
Pembrolizumab-Based Regimen Yields PFS Benefit in Platinum-Resistant Ovarian Cancer #ovca #oncology
www.onclive.com/view/pembrol...
0
0
0
0
🩸 Plasma-activated media selectively induces apoptotic death via an orchestrated oxidative stress pathway in high-grade serous ovarian cancer cells
👉 buff.ly/9W71sWg
🥼 @Nirmalrob
#OVCA #Apoptosis #HGSOC
0
0
0
0
FDA Grants Fast Track Designation to INX-315 in CCNE1-Amplified, Platinum-Resistant Ovarian Cancer #ovca #oncology
www.onclive.com/view/fda-gra...
0
0
0
0
PARP Inhibitor Rechallenge With Niraparib Plus Bevacizumab Is Feasible, Active in Recurrent Ovarian Cancer #SGO25 #ovca #gynsm www.onclive.com/view/parp-in...
1
0
0
0
Nemvaleukin Fails to Show OS Benefit Over Chemotherapy in Platinum-Resistant Ovarian Cancer #ovca #oncology
www.onclive.com/view/nemvale...
0
0
0
0
Ocular AEs From Mirvetuximab Soravtansine Do Not Impact HRQOL in FRα+ Platinum-Resistant Ovarian Cancer #SGOMtg #SGO25 #ovca #oncology www.onclive.com/view/ocular-...
0
0
0
0
Frontline Maintenance With Niraparib Plus Bevacizumab Is Active in Advanced Ovarian Cancer #SGOMtg #SGO2025 #ovca
www.onclive.com/view/frontli...
0
0
0
0
Updated MIRASOL Data Support Mirvetuximab Soravtansine as SOC for FRα+ Platinum-Resistant Ovarian Cancer #SGOMtg #AM25IMPACT #SGO2025 #ovca #gyncsm www.onclive.com/view/updated...
1
0
0
0
ADC Development in Ovarian Cancer: What's Next for FRa and Beyond? #SGOmtg #ovca #oncology www.onclive.com/view/adc-dev...
1
0
0
0
Trend Towards Favorable DFS Observed With Cisplatin/Paclitaxel in HRD Advanced Ovarian Cancer #SGOmtg #ovca #gynsm www.onclive.com/view/trend-t...
0
0
0
0
ADC Anetumab Ravtansine Does Not Improve PFS vs Paclitaxel in High-Grade Serous Ovarian Cancer #ovca #gynsm #oncology www.onclive.com/view/adc-ane...
0
0
0
0
Senaparib Receives NMPA Approval As First-Line Maintenance in Ovarian Cancer #ovca #oncology www.onclive.com/view/senapar...
0
0
0
0
WATCH: Lan Coffman, MD, PhD presents updated OS and safety data from the phase 3 MIRASOL trial of mirvetuximab soravtansine vs chemotherapy in patients with platinum-resistant ovarian cancer and high FRα expression. @upmchillmancc.bsky.social #ovca #oncology www.onclive.com/view/phase-3...
1
0
0
0
IMNN-001 Plus Perioperative Chemotherapy Maintains OS Benefit in Newly Diagnosed Advanced Ovarian Cancer #ovca #oncology www.onclive.com/view/imnn-01...
0
0
0
0
1
0
0
0